Effects of a PPARG gene variant on obesity characteristics in Brazil

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 7, 2007, Pages 927-932

  Mattevi, V S ^a,b   Zembrzuski, V M ^b   Hutz, Mara H ^b  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Genetic susceptibility; Multifactorial diseases; Obesity; PPARG gene

Indexed keywords

ALANINE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE; TRIACYLGLYCEROL;

ADULT; ALLELE; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; BRAZIL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENERGY METABOLISM; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPE; POLYMERASE CHAIN REACTION; SEX DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL; WILD TYPE;

LONCHOCARPUS GLAUCIFOLIUS;

EID: 34547768729     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006005000114     Document Type: Article

References (28)

1. Palou A, Serra F, Bonet ML, Pico C. Obesity: molecular bases of a multifactorial problem. Eur J Nutr 2000; 39: 127-144.
2. Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr 1995; 4: 281-299.
3. Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz M, Moller DE, et al. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun 1996; 224: 431-437.
4. Walczak R, Tontonoz P. PPARadigms and PPARadoxes: expanding roles for PPARgamma in the control of lipid metabolism. J Lipid Res 2002; 43: 177-186.
5. Farmer S. Transcriptional control of adipogenesis: interplay between C/ EBPs and PPARγ in regulating adipocyte gone expression. In: Medeiros-Neto G (Editor), Progress in obesity research. Paris: John Libbey Eurotext; 2003. p 15-18.
6. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, et al. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998; 20: 284-287.
7. Masugi J, Tamori Y, Mori H, Koike T, Kasuga M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipo-genesis. Biochem Biophys Res Commun 2000; 268: 178-182.
8. Hasstedt SJ, Ren QF, Teng K, Elbein SC. Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 2001; 86: 536-541.
9. Mattevi VS, Zembrzuski VM, Hutz MH. Association analysis of genes involved in the leptin-signaling pathway with obesity in Brazil. Int J Obes Relat Metab Disord 2002; 26: 1179-1185.
10. WHO (World Health Organization). Obesity: preventing and managing the global spidemic. Report of a WHO consultation on obesity 1997 3-5 June; Geneva. Geneva: World Health Organization; 1998.
11. Friedewakl WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
12. Yen CJ, Beamer BA, Negri C, Silver K, Brown KA, Yamall DP, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gone in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 1997; 241: 270-274.
13. Meirhaeghe A, Amouyel P. Impact of genetic variation of PPAR gamma in humans. Mol Genet Metab 2004; 83: 93-102.
14. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycomic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group. Diabetes 1997; 46: 433-439.
15. Nozue T, Michishita I, Minagawa F, Genda A. Troglitazone directly increases HDL cholesterol levels. Diabetes Care 1999; 22: 355-356.
16. Akiyama TE, Sakal S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002; 22: 2607-2619.
17. Caramori ML, Canani LH, Costa LA, Gross JL. The human peroxisome proliferator-activated, receptor gamma2 (PPARgamma2) Pro12Ala polymorphism is associated with decreased risk of diabetic nephropathy in patients with type 2 diabetes. Diabetes 2003; 52: 3010-3013.
18. Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scalissi N, et al. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes Metab 2005; 7: 605-611.
19. Vieira-Filho JP, Reis AF, Kasamatsu TS, Tavares EF, Franco LJ, Matioli SR, et al. Influence of the polymorphisms Tpr64Arg in the beta 3-adrenergic receptor gene and Pro12Ala in the PPAR gamma 2 gene on metabolic syndrome-related phenotypes in an indigenous population of the Brazilian Amazon. Diabetes Care 2004; 27: 621-622.
20. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, et al. The peroxisome proliferator-activated receptor-gamma2 Pro12Ala variant: association with type 2 diabetes and trait differences. Diabetes 2001; 50: 886-890.
21. Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa MI. Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia 2001; 44: 925-926.
22. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR. Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001; 50: 2172-2176.
23. Masud S, Ye S. Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 2003; 40: 773-780.
24. Tonjes A, Scholz M, Loeffler M, Stumvoll M. Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on non-diabetic individuals. Diabetes Care 2006; 29: 2489-2497.
25. Memisoglu A, Hankinson SE, Manson JE, Colditz GA, Hunter DJ. Lack of association of the codon 12 polymorphism of the peroxisome prolifarator-activated receptor gamma gene with breast cancer and body mass. Pharmacogenetics 2002; 12: 597-603.
26. Lai K, Harnish DC, Evans MJ. Estrogen receptor alpha regulates expression of the orphan receptor small heterodimer partner. J Biol Chem 2003; 278: 36418-36429.
27. Cardona F, Morcillo S, Gonzalo-Marin M, Garrido-Sanchez L, Macias-Gonzalez M, Tinahones FJ. Pro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome. Clin Chem 2006; 52: 1920-1925.
28. Fajas L. Adipogenesis: a cross-talk between cell proliferation and call differentiation. Ann Med 2003; 35: 79-85.